ClinicalTrials.gg
RecruitingNCT06630949D3-CrUpdated Oct 8, 2024

D3-Creatine and Skeletal Muscle in Older Adults

An observational study in Aging and Muscle Loss, sponsored by McMaster University. Recruiting at 1 site in Canada. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-08.

Sponsored by McMaster University · Observational

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
350
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Muscular Atrophy with a site in Canada — 1 open to participants now, 2 under way, 1 of them phase 3. Muscular Atrophy · Canada.

Started
2023
with 4 others
Observational
2 of 29
1 open now
Registered
28th of 29
by date
Lead sponsor
8 of 29
McMaster University

Among the 29 studies in Muscular Atrophy with a site in Canada, this one is one of 5 that started in 2023, is one of 2 observational ones, and was the 28th registered.

Muscular Atrophy

413 studies on the registry are indexed under Muscular Atrophy; 76 are open to participants now.

Browse Muscular Atrophy studies →

Open to participants now

1 of the 29 studies in Muscular Atrophy with a site in Canada is open now.

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 51 Muscular Atrophy studies recruiting now, 25 (49%) set no upper age limit and 13 (25%) stop at 75 or younger; 4 take children under 18; 16 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Muscular Atrophy with a site in Canada, or all of them as a file.
02

Study summary

The age-related decline in muscle mass and strength are collectively referred to as sarcopenia. However, the tools currently employed to assess skeletal muscle mass (SMM) (e.g., Dual-energy Xray Absorptiometry; DXA) have substantial drawbacks, and it is known that DXA-lean soft tissue (LST) is generally not associated with health outcomes of interest. Thus, the investigators propose using a novel, non-invasive, stable isotope-labelled probe (Deuterium (D)-labelled creatine (D3-creatine; D3-Cr)) to measure skeletal muscle mass in a large cohort of older individuals. The development and employment of new methods to accurately quantify the biological substrate of sarcopenia, skeletal muscle, are critical for the measure to remain clinically relevant. The plan is to measure 350 persons from the recently established (M3) prospective cohort. There will be measurement of lean soft tissue LST and appendicular LST (aLST) using DXA and compared to D3-Cr-measured SMM (D3-Cr-SMM) at baseline, 12mo, and 24mo (2yr) of follow-up. Physical mobility will also be measured (using various instruments).

Read the detailed description

The tools currently employed to assess skeletal muscle mass (SMM), including DXA, have substantial drawbacks. DXA does not measure muscle per se but provides an assessment of lean soft tissue (LST) as a proxy for skeletal muscle. Even if confined to the appendages (aLST), DXA assessments include many non-muscle constituents (e.g., connective tissue, water), which are poorly and inconsistently related to mobility and falls with aging. As a superior measure to DXA, the investigators will use a novel, stable isotope-labelled probe to measure SMM. This method uses the oral ingestion of a small dose of deuterium (D)-labelled creatine (D3-creatine; D3-Cr), which is irreversibly converted to creatinine when taken up by skeletal muscle. The dilution of the labelled creatinine provides a safe, non-invasive, and highly accurate measure of SMM. The utilization of D3-Cr-measured SMM (D3-Cr-SMM) requires no specific diet and requires only the collection of a spot urine sample.

The plan is to recruit a sub-sample of older Canadians between 60 and 80 living in the greater Hamilton-Toronto area. Participants will be recruited through the MacM3 (M3) cohort study. MacM3 will enroll a sample of 2,000 participants from a pre-recruited representative sample of more than 10,000 older adults living in the greater Hamilton and Toronto areas who consented to be contacted for further research as part of a larger research platform. From this pool of 2000 individuals in MacM3, the plan is to recruit 350 people. Participants will be classified across the three levels of mobility limitations based on the MacM3 screening criteria of preclinical mobility limitation (i.e., able to manage without difficulty - no mobility limitation, able to manage without difficulty but sometimes with task modification - early mobility limitation, and able to manage with minor difficulty - minor mobility limitation, which will provide valuable insight into whether changes in D3-Cr-SMM are associated with a change in categorical mobility status.

The proposed research design is a prospective cohort study including 350 older (65-80 y) men and women. All participants will undergo muscle mass assessments via D3-Cr, body composition (LST, aLST, fat mass) via DXA, and dietary intake by 24h recall (ASA24) at baseline, 1y and 2y of follow-up. Performance-based assessments of physical function, mobility status and muscular strength will also be conducted at baseline, 1y and 2y of follow-up. During the quarterly follow-up phone calls, all participants will be screened limitation screening questions (see inclusion criteria), allowing us to capture changes in mobility status (i.e., no, early, minor or major mobility limitation) over time.

03

Conditions studied

  • Aging
  • Muscle Loss

Keywords

  • aging
  • muscle
  • stable isotope tracer
  • mobility
  • sarcopenia
  • creatine
  • creatinine
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The cohort will be a sub-sample from the McMaster Monitoring My Mobility (MacM3) cohort, a newly founded research cohort. The MacM3 cohort is a longitudinal study of community-dwelling older Canadians (age 60-80 y at baseline) with different levels of mobility limitation (i.e., able to manage without difficulty - no mobility limitation; able to manage without difficulty but with task modification - early mobility limitation; and able to manage with minor difficulty - minor mobility limitation) collecting detailed mobility and health data on participants over two years of follow-up.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants will be considered eligible for this study if they are

  • Between 60 and 80y (inclusive),
  • Reside in the local (i.e., within 60km of Hamilton) community; and
  • Are willing and able to provide written .

Participants must fall into one of three self-reported mobility limitations based on validated screening criteria via a structured phone interview. Potential participants will be asked whether they have any difficulty:

  • Walking 800m;
  • Climbing ten steps; and
  • Transferring from/into a car or bus.

Response options include:

  • Managing without difficulty;
  • Managing without difficulty but with task modification; or
  • Managing with minor difficulty.

Exclusion criteria

Exclusion Criteria:

  • Participants who self-report more than minor difficulty will be considered to have a mobility disability and excluded.
  • Participants who cannot speak or read English will also be excluded.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
350 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Muscle mass

    D3-creatine-measured muscle mass

    Time frame: 2 years

  2. Lean tissue mass

    DXA-measured lean tissue mass

    Time frame: 2 years

Secondary outcomes

  1. Questionnaire Mobility

    Questionnaire-based assessment of participant's physical mobility

    Time frame: 2 years

  2. SPPB

    Short physical performance battery (SPPB)

    Time frame: 2 years

  3. Timed up and go

    Participant starts in a seated position, stands up upon go signal, walks 3 meters, turns around, walks back to the chair and sits down. The time stops when the patient is seated

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • Exercise Metabolism Research Laboratory, McMaster Univeristy
    Hamilton, Ontario L8S 4K1, Canada
    Recruiting
    • Stuart M Phillips, Ph.D. · Contactphillis@mcmaster.ca · 905-525-9140
    • Stuart M Phillips, Ph.D. · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided — We will evaluate all requests to obtain IPD when the study is complete.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Dec 2026, 38 months after the start.

Of 36 non-industry observational studies under Muscular Atrophy, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 66. This study's planned 38 months is above that.

Counting every sponsor, half of 38 studies reached it within 35 months; a quarter within 18 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2024
First posted
Oct 8, 2024
StartActual
Oct 1, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 30, 2027
Last update
Oct 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06630949
Responsible party
Stuart Phillips (Professor and Canada Research Chair, McMaster University) — Principal investigator
First posted
Oct 8, 2024
Start date
Oct 1, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Oct 8, 2024

Study contacts

Shalini Jaisankar Sumathi, MS
Contact
jaisans@mcmaster.ca
905-525-9140
Stuart Phillips
principal investigator · McMaster University, Department of Kinesiology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion